| Description | Peramivir (BCX1812) is a highly selective influenza A and B neuraminidase inhibitor with antiviral activity and anti-cytokine effects, which can be used in the study of novel coronavirus and influenza virus infections. |
| In vitro | Peramivir（2-10 μM，6-12 小时）可抑制 LPS 诱导的 hPBMCs 细胞因子释放[4]。Peramivir（0.3125-40 μM，4 小时）对巨噬细胞无毒[4]。 |
| In vivo | Peramivir（20-60 mg/kg，腹腔注射，单次剂量）可抑制 LPS 诱导的细胞因子风暴，减轻急性肺损伤，并延长细胞因子风暴综合征小鼠模型的存活时间[4]；在乙型流感病毒感染的免疫抑制小鼠模型中，Peramivir（75 mg/kg，肌肉注射，每天一次，连续 7 天）可挽救 BR/08 致命攻击的 BALB scid 小鼠 [5]。 |
| Target activity | NA:IC50: 0.9-4.3 nM |
| Synonyms | RWJ270201, BCX 1812, BCX1812, RWJ 270201 |
| molecular weight | 328.41 |
| Molecular formula | C15H28N4O4 |
| CAS | 330600-85-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: < 1 mg/mL (insoluble or slightly soluble.) |
| References | 1. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther. 2015 Feb 2;57(1461):17-9. 2. Sato M, Iet al.Influenza Viral Load and Peramivir Kinetics after Single Administration and Proposal of Regimens for Peramivir Administration against Resistant Variants. Antimicrob Agents Chemother. 2014 Dec 29. pii: AAC.04263-14. 3. Komeda T, et al.Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation. J Infect Chemother. 2014 Nov 26. pii: S1341-321X(14)00402-4. 4. Hata A, et al.Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther. 2014 Oct 24;8:2017-38. 5. Zhang CX, et al. Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects. Front Immunol. 2022 Feb 28;13:856327. 6. Pascua PNQ, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci Rep. 2017 Aug 4;7(1):7345. |